[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-333271-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-333271-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","sialyl-tn-serves-as-a-potential-therapeutic-target-for-ovarian-cancer-research-open-access","Sialyl-Tn serves as a potential therapeutic target for ovarian cancer - Research Open Access","","Background: Ovarian cancer remains the deadliest gynecologic cancer in the United States, and treatment progress has been limited despite improved overall survival. This report further validates a humanized anti-SialylTn antibody-drug conjugate (anti-STn-ADC) and evaluates STn as a potential patient-identifying marker. Methods: Testing includes STn-positive/negative cell lines, patient-derived organoids, and patient-derived xenografts. A custom ELISA quantifies serum STn and assesses correlation with tumor STn status, stage, survival, and CA-125 performance, with comparison to immunohistochemistry in selected samples. Results and conclusions: Preclinical data support anti-STn-ADC viability and suggest STn-ELISA may complement IHC despite limited diagnostic added value versus CA-125.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/sialyl-tn-serves-as-a-potential-therapeutic-target-for-ovarian-cancer-research-open-access/333271/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/sialyl-tn-serves-as-a-potential-therapeutic-target-for-ovarian-cancer-research-open-access/333271.png","ImageObject",300,407,{"name":42,"@type":43},"Lucas Martin","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-24","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main therapeutic focus of the study?","Question",{"text":63,"@type":64},"The study evaluates a humanized anti-SialylTn antibody-drug conjugate (anti-STn-ADC) as a potential therapeutic option for ovarian cancer.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did the researchers test anti-STn-ADC across ovarian cancer models?",{"text":68,"@type":64},"They tested it in STn-positive and STn-negative ovarian cancer cell lines, patient-derived organoid (PDO) models, and patient-derived xenograft (PDX) models.",{"name":70,"@type":61,"acceptedAnswer":71},"Why was serum STn measurement evaluated, and what tool was used?",{"text":72,"@type":64},"Serum STn levels were assessed to see whether they reflect tumor STn positivity and could help identify patients. A custom ELISA with high specificity and sensitivity was developed to measure circulating STn.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},333271,1790666641,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":109,"preview_page_count":4},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Al-Alem etal. Journal of Ovarian Research (2024) 17:71 Journal of Ovarian Research  \n[https://doi.org/10.1186/s13048-024-01397-1](https://doi.org/10.1186/s13048-024-01397-1)  \nRESEARCH Open Access  \nSialyl-Tn serves as a potential therapeutic target for ovarian cancer  \nLinah Al-Alem 1,2, Jillian M. Prendergast3, Justin Clark3, Bianca Zarrella 1, Dominique T. Zarrella 1, Sarah J. Hill5,6,7, Whitfield B. Growdon 1,2,4, Venkatesh Pooladanda 1,2, David R. Spriggs8,9, Daniel Cramer 10, Kevin M. Elias 11, Rawan I. Nazer3, Steven J. Skates 12, Jeff Behrens3, Daniel T. Dransfield3 and Bo R. Rueda 1,2,4*  \nAbstract  \nBackground Ovarian cancer remains the deadliest of the gynecologic cancers in the United States. There have been limited advances in treatment strategies that have seen marked increases in overall survival. Thus, it is essential to continue developing and validating new treatment strategies and markers to identify patients who would benefit from the new strategy. In this report, we sought to further validate applications for a novel humanized anti-SialylTn antibody-drug conjugate (anti-STn-ADC) in ovarian cancer.  \nMethods We aimed to further test a humanized anti-STn-ADC in sialyl-Tn (STn) positive and negative ovarian cancer cell line, patient-derived organoid (PDO), and patient-derived xenograft (PDX) models. Furthermore, we sought to determine whether serum STn levels would reflect STn positivity in the tumor samples enabling us to identify patients that an anti-STn-ADC strategy would best serve. We developed a custom ELISA with high specificity and sensitivity, that was used to assess whether circulating STn levels would correlate with stage, progression-free survival, overall survival, and its value in augmenting CA-125 as a diagnostic. Lastly, we assessed whether the serum levels reflected what was observed via immunohistochemical analysis in a subset of tumor samples.  \nResults Our in vitro experiments further define the specificity of the anti-STn-ADC. The ovarian cancer PDO, and PDX models provide additional support for an anti-STn-ADC-based strategy for targeting ovarian cancer. The custom serum ELISA was informative in potential triaging of patients with elevated levels of STn. However, it was not sensitive enough to add value to existing CA-125 levels for a diagnostic. While the ELISA identified non-serous ovarian tumors with low CA-125 levels, the sample numbers were too small to provide any confidence the STn ELISA would meaningfully add to CA-125 for diagnosis.  \nConclusions Our preclinical data support the concept that an anti-STn-ADC may be a viable option for treating patients with elevated STn levels. Moreover, our STn-based ELISA could complement IHC in identifying patients with whom an anti-STn-based strategy might be more effective.  \nKeywords Sialyl-Tn, Ovarian cancer, Companion diagnostic, Targeted therapy  \n*Correspondence:  \nBo R. Rueda [brueda@mgh.harvard.edu](brueda@mgh.harvard.edu)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/l](http://creativecommons.org/l)icenses/by/4.0/. The Creative Commons Public Domain Dedication waiv","cbCaigR9aiVFF17M","https://ap.wps.com/l/cbCaigR9aiVFF17M","pdf",5087863,16,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What is the main therapeutic focus of the study?\",\"answer\":\"The study evaluates a humanized anti-SialylTn antibody-drug conjugate (anti-STn-ADC) as a potential therapeutic option for ovarian cancer.\"},{\"question\":\"How did the researchers test anti-STn-ADC across ovarian cancer models?\",\"answer\":\"They tested it in STn-positive and STn-negative ovarian cancer cell lines, patient-derived organoid (PDO) models, and patient-derived xenograft (PDX) models.\"},{\"question\":\"Why was serum STn measurement evaluated, and what tool was used?\",\"answer\":\"Serum STn levels were assessed to see whether they reflect tumor STn positivity and could help identify patients. A custom ELISA with high specificity and sensitivity was developed to measure circulating STn.\"}]","Sialyl-Tn serves as a potential therapeutic target for ovarian cancer - Research Open Access | PDF",1790001743]